کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5697481 | 1410309 | 2016 | 12 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Risque thromboembolique en oncologie : réalités, actualités et perspectives
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
hypercoagulabilityHypercoagulabilitéPulmonary embolism - آمبولی ریهEmbolie pulmonaire - آمبولی ریهVenous thromboembolic disease - بیماری ترومبوآمبولیک وریدیMaladie thromboembolique veineuse - ترومبوآمبولی وریدیDeep vein thrombosis - ترومبوز سیاهرگی عمقیThrombose veineuse profonde - ترومبوز وریدی عمیقThrombin generation - تولید ترومبینCancer - سرطانLow molecular weight heparin - هپارین با وزن مولکولی کم Héparines de bas poids moléculaire - هپارین های وزن مولکولی کم
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
تومور شناسی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Risque thromboembolique en oncologie : réalités, actualités et perspectives Risque thromboembolique en oncologie : réalités, actualités et perspectives](/preview/png/5697481.png)
چکیده انگلیسی
Cancer is a leading cause of venous thromboembolism (VTE) and vice versa. Pulmonary embolism is the second cause of death in cancer patients. Tumor progression is associated with coagulation activation. The pathogenesis of thrombosis during cancer is particularly complex stemming from multiple connections of this disease with both systems of inflammation and hemostasis. The risk of VTE depends on cancer type and the stage of the disease, the anticancer treatments and the time since cancer diagnosis as well as on the presence of patient-related risk factors (i.e. age, obesity, previous history of VTE, underlying diseasesâ¦). The presence of other precipitating factors and the duration of the exposure to them are also key elements in the assessment of such a thrombotic risk. It is therefore important to identify all the VTE risk factors to identify patients at high vascular risk and to determine the period during which this risk is significantly increased. The integration of biomarkers of hypercoagulability in proposed risk assessment models for VTE will improve their capacity to identify patients eligible for pharmacological thromboprophylaxis. In this review, we report the current status of knowledge on the connection between cancer and hypercoagulability, the numerous risk factors for VTE must be identified in cancer patients and the best methodology to build a more accurate assessment of this vascular risk in such a complex medical context.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Bulletin du Cancer - Volume 103, Issue 9, September 2016, Pages 764-775
Journal: Bulletin du Cancer - Volume 103, Issue 9, September 2016, Pages 764-775
نویسندگان
Grigoris T. Gerotziafas, Ismail Elalamy,